אלטרובניר 25 מ"ג - Eltrovenir 25 mg

EltroVenir is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). EltroVenir is indicated for the treatment of paediatric patients aged 6 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). EltroVenir is indicated for the treatment of adult patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. EltroVenir is indicated for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. EltroVenir is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 6 years and older with severe aplastic anemia.